Lupus Erythematosus, Systemic
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.
Subtype terms (2)
More specific conditions that are subtypes of Lupus Erythematosus, Systemic in the MeSH hierarchy.
- Lupus Nephritis
128 drugs (52 approved, 76 experimental)
- Lupus Vasculitis, Central Nervous System
1 drug experimental
Drugs by status
Approved for this indication (7)
Phase 4 trials (38)
- milnacipran
- inactivated influenza vaccine
- hpv 16/18 vaccine
- atorvastatin
- mycophenolate
- calcitriol
- simvastatin
- corn
- methylprednisolone
- quinapril
- rituximab
- ibandronate
- icosapent ethyl
- pioglitazone
- sulfamethoxazole
- subunit herpes zoster vaccine
- rosuvastatin
- trimethoprim
- pneumococcal 13-valent conjugate vaccine
- dapagliflozin
- Telitacicept
- cyclophosphamide
- hydrocortisone
- 23-valent pneumococcal polysaccharide vaccine
- calcium
- azathioprine
- multivitamins
- conjugated equine estrogens
- tacrolimus
- acetylsalicylic acid
- +8 more
Phase 3 trials (46)
- tabalumab
- atacicept
- live, attenuated, dengue serotype 1, 2, 3, 4 virus
- vay736
- ocrelizumab
- dexchlorpheniramine maleate
- abatacept
- leuprolide
- pyridoxine
- prasterone
- mrna-1273
- zishenqinggan
- upadacitinib
- isoniazid
- ethinyl estradiol
- folic acid
- warfarin
- mil62
- blisibimod
- acetaminophen
- phosphate
- ramipril
- infliximab
- vitamin d3
- umbilical cord mesenchymal stem cells
- dapirolizumab pegol
- norethindrone
- cenerimod
- medroxyprogesterone
- naltrexone
- +16 more
Phase 2 trials (131)
- gr1603
- tqb3702
- 99mtc ec20
- sctb35
- ds-7011a
- afimetoran
- janssen SARS-CoV2 vaccine
- lulizumab pegol
- riboflavin
- etanercept
- cytarabine
- bortezomib
- clopidogrel
- kp104
- e6742
- isa-51
- Zetomipzomib
- alpn-101
- jbt-101
- bone marrow derived mesenchymal stem cells
- pf-04236921
- evobrutinib
- medi7734
- gdc-0853
- memantine
- b multivitamins
- efalizumab
- sodium chloride
- amg 592
- fish oil
- +101 more
Phase 1 trials (117)
- cnty-101
- glpg3970
- famotidine
- ata3219
- telisotuzumab vedodin
- cd20/bcma-directed car-t cells
- ontegimod
- omicron covid-19 vaccine (vero cell), inactivated
- nnc0114-0006
- lcar-aio cells
- jwcar201
- qls4131
- azd5492
- amg-811
- cd19 car-nk cells
- shr-1314
- allogeneic hematopoietic stem cells
- sbi-087
- ol-108
- cb-010
- omalizumab
- utaa91
- rd06-05
- mor202
- alemtuzumab
- ctx112
- anti-bcma/cd70 car-t cells
- allogeneic gamma-delta t cells
- sc291
- cc-93269
- +87 more
Other trials (23)
- autologous mononuclear stem cell
- im19 car-t cells
- duloxetine
- estradiol
- brl-301
- trebananib
- clofarabine
- interleukin 23
- cm355
- creatine
- cobalamin
- tislelizumab
- dipyridamole
- equecabtagene autoleucel
- vitamin c
- hn2301
- fludeoxyglucose f-18
- yellow fever vaccine 17d strain
- pantothenic acid
- modafinil
- gpc3 car-t cell
- oshadi d
- krill oil
Organizations
Organization Involved with Phase 4 Indications (34)
- Forest Laboratories
- AstraZeneca
- Sanofi-Synthelabo
- Ampel BioSolutions, LLC
- GlaxoSmithKline
- Mallinckrodt
- Oklahoma Medical Research Foundation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- University of London
- Duke University
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Johns Hopkins University
- Loma Linda University
- Mahidol University
- Michigan State University
- New York University
- Northwell Health
- Stanford University
- University of Toronto
- Utrecht University
- Chinese University of Hong Kong
- University of Chicago
- Zhejiang University
- Jiao Tong University
- National University of Singapore
- Government of Mexico
- University of Sao Paulo
- Universidad Autonoma de Barcelona
- National Autonomous University of Mexico
- University of Paris
- +4 more
Organization Involved with Phase 3 Indications (50)
- Incyte
- Genelabs Technologies
- UCB
- Cephalon
- Bristol-Myers Squibb
- Roche
- Merck Serono
- Eli Lilly
- Genentech
- Merck KGaA
- Pfizer
- Sanofi
- Novartis
- Anthera Pharmaceuticals
- ImmuPharma
- La Jolla Pharmaceutical Company
- RemeGen
- National Institutes of Health (NIH)
- National Center for Research Resources (NCRR)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Medical University of Graz
- Tzu Chi University
- Hoosier Cancer Research Network
- McGill University
- Northwestern University
- Ohio State University
- Radboud University
- Shanghai University of Traditional Chinese Medicine
- University of Groningen
- University of Michigan
- +20 more
Organization Involved with Phase 2 Indications (107)
- PPD
- Ablynx
- AbbVie
- Actelion
- Active Biotech AB
- Seattle Genetics
- Basilea Pharmaceutica
- Celgene
- Galapagos NV
- Amgen
- Gilead Sciences
- Immunomedics
- MedImmune
- Biogen
- Astion Pharma A/S
- Boston Pharmaceuticals
- Endocyte
- Invion, Inc.
- Nektar Therapeutics
- Neovacs
- North China Pharmaceutical Group Corporation
- Rigel Pharmaceuticals
- Resolve Therapeutics
- Theramab LLC
- Teva
- Iltoo Pharma
- Medsenic
- ZonMw: The Netherlands Organisation for Health Research and Development
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- +77 more
Organization Involved with Phase 1 Indications (34)
- Millennium Pharmaceuticals
- Emergent BioSolutions
- Centocor
- Novo Nordisk
- Grifols
- Wyeth
- Argos Therapeutics
- Baxalta
- Biocon Limited
- Shanghai GeneChem Co., Ltd.
- Boehringer Ingelheim
- National Heart, Lung, and Blood Institute (NHLBI)
- Hebei University
- New York Medical College
- Pontificia Universidad Catolica de Chile
- Tufts University
- Wayne State University
- University of California, Irvine
- Metroplex Clinical Research
- Alliance Foundation Trials
- IDT Australia Ltd.
- Richmond Pharmacology
- California Clinical Trials
- Mitsubishi Tanabe
- Noxxon AG
- University of Texas at Houston
- University of Alabama, Birmingham
- Eurofins
- ACM Global Laboratories
- Acea Bio
- +4 more
Organization Involved with Other Experimental Indications (15)
- Aker Biomarine Antarctic AS
- Oshadi Drug Administration
- Dr. Jesus Gutierrez Stone
- Shahid Beheshti University of Medical Sciences
- Rockefeller University
- Alexandria University
- Anhui Medical University
- Federal University of Minas Gerais
- Jilin University
- Shengjing Hospital
- University of Pisa
- Xinjiang Medical University
- University of Leipzig
- University of Minnesota
- Hebrew University